Capricor Therapeutics (NASDAQ:CAPR) Rating Increased to Strong-Buy at B. Riley

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) was upgraded by investment analysts at B. Riley to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other research analysts have also recently issued reports on CAPR. HC Wainwright reissued a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday. Oppenheimer reduced their price target on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday. Roth Capital restated a "buy" rating and issued a $31.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, June 17th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $33.75.

Capricor Therapeutics Stock Up 1.3%

Shares of CAPR stock opened at $10.18 on Wednesday. The business's fifty day moving average is $10.89 and its 200 day moving average is $12.38. The stock has a market cap of $465.02 million, a price-to-earnings ratio of -7.17 and a beta of 0.84. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same period in the prior year, the company earned ($0.31) earnings per share. Equities research analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock worth $31,420,000 after purchasing an additional 700,243 shares during the period. Farallon Capital Management LLC purchased a new stake in Capricor Therapeutics in the fourth quarter worth about $31,056,000. Geode Capital Management LLC raised its stake in shares of Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock worth $12,139,000 after buying an additional 241,279 shares during the period. Woodline Partners LP raised its stake in shares of Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company's stock worth $6,921,000 after buying an additional 99,384 shares during the period. Finally, Altium Capital Management LLC lifted its position in shares of Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after buying an additional 429,000 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.